Precigen, Inc. (PGEN)

NASDAQ: PGEN · Real-Time Price · USD
4.590
+0.330 (7.75%)
At close: Aug 27, 2025, 4:00 PM
4.590
0.00 (0.00%)
Pre-market: Aug 28, 2025, 8:55 AM EDT
7.75%
Market Cap1.37B
Revenue (ttm)4.34M
Net Income (ttm)-124.50M
Shares Out 297.97M
EPS (ttm)-0.43
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume13,324,879
Open4.350
Previous Close4.260
Day's Range4.140 - 4.590
52-Week Range0.651 - 4.590
Beta1.87
AnalystsBuy
Price Target7.50 (+63.4%)
Earnings DateAug 12, 2025

About PGEN

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1998
Employees 143
Stock Exchange NASDAQ
Ticker Symbol PGEN
Full Company Profile

Financial Performance

In 2024, Precigen's revenue was $3.93 million, a decrease of -36.95% compared to the previous year's $6.23 million. Losses were -$126.24 million, 31.6% more than in 2023.

Financial Statements

Analyst Summary

According to 5 analysts, the average rating for PGEN stock is "Buy." The 12-month stock price target is $7.5, which is an increase of 63.40% from the latest price.

Price Target
$7.5
(63.40% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright

GERMANTOWN, Md. , Aug. 25, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of pat...

3 days ago - PRNewsWire

Undercovered Dozen: Precigen, ONEOK, Bitmine And More

This week's Undercovered Dozen highlights 12 lesser-known stocks and ETFs with compelling investment theses and recent catalysts. Standouts include CGDV's market-beating performance, DIVO's retirement...

Other symbols: BMNROKE
5 days ago - Seeking Alpha

Precigen: This Billion-Dollar Approval Is Still Undervalued

PAPZIMEOS's full FDA approval for RRP is a decisive, de-risking event and validates Precigen's immunotherapy platform. PAPZIMEOS targets a significant unmet need, with potential for $1B+ peak sales, t...

12 days ago - Seeking Alpha

Why Is Precigen Stock Surging On Friday?

On Friday, the U.S. Food and Drug Administration (FDA) approved Precigen Inc.'s PGEN Papzimeos (zopapogene imadenovec-drba) for adult patients with recurrent respiratory papillomatosis (RRP).

12 days ago - Benzinga

US FDA approves Precigen's immunotherapy for rare respiratory disease

The U.S. Food and Drug Administration has approved Precigen's immunotherapy to treat adults with a rare respiratory disease, making it the first treatment for the condition to receive the health regul...

13 days ago - Reuters

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with RRP PAPZIMEOS received full approval from the FD...

13 days ago - PRNewsWire

Precigen: August Is Pivotal For This Biotech Innovator

Precigen's future hinges on the FDA's approval of PRGN-2012, with a pivotal decision expected August 27, 2025. PRGN-2012 shows strong efficacy and safety, potentially transforming the treatment of Rec...

7 weeks ago - Seeking Alpha

Precigen Reports First Quarter 2025 Financial Results and Business Updates

PRGN-2012 has the potential to be the first- and best-in-class treatment for RRP Company's BLA for PRGN-2012 for the treatment of adults with RRP is under priority review by the FDA with a PDUFA targe...

3 months ago - PRNewsWire

Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

– International event will raise awareness and bring together RRP patients , caregivers, and the healthcare community supporting them – – Recurrent respiratory papillomatosis is a rare, debilitating, ...

4 months ago - PRNewsWire

Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript

Precigen, Inc. (NASDAQ:PGEN) Q4 2024 Earnings Conference Call March 19, 2025 4:30 PM ET Company Participants Steven Harasym - IR Helen Sabzevari - President and CEO Rutul Shah - COO Phil Tennant - CC...

5 months ago - Seeking Alpha

Precigen Reports Full Year 2024 Financial Results and Business Updates

FDA granted priority review to Company's BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis and set PDUFA target action date for August 27, 2025 Results from pivot...

5 months ago - PRNewsWire

Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th

GERMANTOWN, Md. , March 13, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives o...

6 months ago - PRNewsWire

Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement

BLA of PRGN-2012 for patients with Recurrent Respiratory Papillomatosis was accepted by FDA with a Priority Review date of August 27th of 2025. Marketing approval of PRGN-2012 for RRP would be huge be...

6 months ago - Seeking Alpha

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

– Priority review reduces the BLA review timeline to 6-months and is granted to therapies that, if approved, would provide significant improvements in the treatment, diagnosis or prevention of serious...

6 months ago - PRNewsWire

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference

–   PRGN-2012 has potential to be first FDA-approved therapeutic for treatment of RRP, a rare and devastating chronic disease  – –   Company completed BLA submission for PRGN-2012 for treatment of adu...

8 months ago - PRNewsWire

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GERMANTOWN, Md. , Jan. 9, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of ...

8 months ago - PRNewsWire

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis

–   PRGN-2012 has the potential to be the first FDA-approved therapeutic for the treatment of adults with RRP, a rare and devastating chronic disease for which the current standard-of-care is repeated...

8 months ago - PRNewsWire

Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

GERMANTOWN, Md. , Dec. 27, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of...

8 months ago - PRNewsWire

Precigen Reports Third Quarter 2024 Financial Results and Business Updates

–   Completed pre-BLA meeting with FDA with full alignment on content of BLA, including CMC module, and path for fourth quarter 2024 rolling BLA submission for PRGN-2012 †  in RRP under accelerated ap...

10 months ago - PRNewsWire

Precigen to Participate in the Stifel 2024 Healthcare Conference

GERMANTOWN, Md. , Nov. 12, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of...

10 months ago - PRNewsWire

Precigen to Participate in the 2024 Cantor Global Healthcare Conference

GERMANTOWN, Md. , Sept. 16, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives o...

1 year ago - PRNewsWire

Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Thursday.

Other symbols: GGRTITN
1 year ago - Benzinga

Precigen, Inc. (PGEN) Q2 2024 Earnings Call Transcript

Precigen, Inc. (NASDAQ:PGEN) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Steven Harasym - VP, IR Helen Sabzevari - President & CEO Harry Thomasian - CFO Phil Tenn...

1 year ago - Seeking Alpha

Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates

– In June 2024, the Company announced groundbreaking pivotal study data for PRGN-2012 gene therapy at the 2024 ASCO annual meeting in which more than half of RRP patients achieved Complete Response – ...

1 year ago - PRNewsWire

Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th

GERMANTOWN, Md. , Aug. 9, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of ...

1 year ago - PRNewsWire